Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 156 participants.
Also called NCT07870681
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 156 participants
- Sponsor
- Registry
-
NCT07870681
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark, Norway
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07870681. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-21 (anticipated); primary completion 2029-01-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE
- Acronym
- Illuminate
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Tociliuzumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Oslo University Hospital
- Collaborator
- Copenhagen University Hospital, Rigshospitalet
- Collaborator
- University Hospital, Akershus
- Collaborator
- Aarhus University Hospital
- Collaborator
- Aalborg University Hospital
- Collaborator
- Odense University Hospital
Record details
- Record id
cardio:ct-nct07870681- Content hash
99d09b03c5fe3a8f34c428b3cdd84ce8fffc813261e513582291f381f8b9e642